Small molecule · Inhibitor of phosphoinositide 3-kinase delta (PI3K-delta) (PIK3CD) · developed by Pharming
Leniolisib is a small-molecule kinase inhibitor that blocks the active site of PI3K-delta, selectively over other PI3K isoforms. It reduces PI3K-delta-driven PIP3 signaling and mTOR/Akt hyperactivity, normalizing B and T cell dysregulation. It is studied in activated PI3K-delta syndrome (APDS).
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 5, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05438407 | Phase 3 | APDS | Active not recruiting | PHAR |
| NCT02859727 | Phase 2/3 | Activated PI3Kdelta Syndrome (APDS); PASLI Disease | Terminated | PHAR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
APDSActivated PI3Kdelta Syndrome (APDS); PASLI Disease
Updated Oct 25, 2026. Something wrong or missing? Report it on the PHAR page.
See PHAR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PHAR catalysts and pipeline →